Benchmark Holdings (GB:BMK) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Benchmark Holdings is set to bolster its focus on advanced nutrition and health sectors by selling its genetics division to Novo Holdings for up to £260 million. This strategic move aims to streamline operations, reduce costs, and strengthen the company’s financial standing by returning capital to shareholders and reducing debt. The sale, expected to complete in early 2025, marks the conclusion of a strategic review initiated earlier this year.
For further insights into GB:BMK stock, check out TipRanks’ Stock Analysis page.
